UBS Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Acadia Pharmaceuticals (ACAD) PT Lowered to $21 at Oppenheimer
September 24, 2025 3:41 PM EDTOppenheimer analyst Matthew Hershenhorn lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $21.00 (from $22.00) while maintaining a Perform rating.
The analyst comments "We anticipated a higher likelihood of ACP-101 missing the primary endpoint of the Ph3 COMPASS-PWS study, driving underperformance today... More
Acadia Pharmaceuticals (ACAD) PT Lowered to $35 at TD Cowen
September 24, 2025 3:38 PM EDTTD Cowen analyst Ritu Baral lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $35.00 (from $39.00) while maintaining a Buy rating.
The analyst comments "ACAD announced that ACP-101 (intranasal carbetocin) missed in the Ph3 Prader Willi study, failing to separate from... More
BofA Son Acadia (ACAD): 'our focus continues to be on the reacceleration of the Daybue launch in Rett syndrome'
September 24, 2025 10:23 AM EDTBofA Securities analyst Tazeen Ahmad reiterated a Neutral rating and $27.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "ACAD announced the ph 3 COMPASS PWS study evaluating ACP-101 (intranasal carbetocin) in patients with hyperphagia in Prader-Willi syndrome (PWS) failed to... More
Baird: 'Acadia shares should come out relatively unscathed after the dust settles'
September 24, 2025 9:29 AM EDTBaird analyst Joel Beatty reiterated an Outperform rating and $31.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "No change to outlook on clinical trial update. This morning, Acadia announced the Phase 3 COMPASS study of ACP-101 in PWS did not meet the... More
BMO Capital: 'expect ACAD shares to decline'
September 24, 2025 8:05 AM EDTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $28.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "ACP-101 miss in PWS represents a meaningful step back in Acadia's R&D development plans. Ph 3 results from the company's COMPASS... More
